Regulatory Milestone for Oral Obesity Drugs Boosts Viking Therapeutics Shares
23.12.2025 - 22:43:04Viking Therapeutics US92686J1060
Shares of Viking Therapeutics gained approximately 2.9% to $36.42 following a pivotal regulatory decision that is reshaping the market for weight-loss medications. The catalyst was the U.S. Food and Drug Administration (FDA) granting its first-ever approval for an oral version of Novo Nordisk’s Wegovy. This development is viewed less as a direct company announcement from Viking and more as a significant positive signal for the entire oral GLP-1 therapy sector.
The FDA’s approval of oral Wegovy (semaglutid 25 mg) for chronic weight management represents a long-anticipated validation for the industry. It formally confirms that tablet-based GLP-1 treatments are both commercially viable and meet regulatory standards, setting a clear precedent Read more...
